

# Paola Fiorani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/195569/publications.pdf>

Version: 2024-02-01

18  
papers

407  
citations

840776

11  
h-index

940533

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

435  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single Mutation in the Linker Domain Confers Protein Flexibility and Camptothecin Resistance to Human Topoisomerase I. <i>Journal of Biological Chemistry</i> , 2003, 278, 43268-43275.	3.4	81
2	Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations. <i>Nucleic Acids Research</i> , 2008, 36, 5645-5651.	14.5	49
3	Effect on DNA relaxation of the single Thr718Ala mutation in human topoisomerase I: a functional and molecular dynamics study. <i>Nucleic Acids Research</i> , 2005, 33, 3339-3350.	14.5	47
4	Interaction between natural compounds and human topoisomerase I. <i>Biological Chemistry</i> , 2012, 393, 1327-1340.	2.5	44
5	Real-Time Label-Free Direct Electronic Monitoring of Topoisomerase Enzyme Binding Kinetics on Graphene. <i>ACS Nano</i> , 2015, 9, 11166-11176.	14.6	43
6	Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. <i>Nucleic Acids Research</i> , 2009, 37, 6849-6858.	14.5	29
7	Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico. <i>Molecular Cancer</i> , 2013, 12, 100.	19.2	29
8	The human topoisomerase 1B Arg634Ala mutation results in camptothecin resistance and loss of inter-domain motion correlation. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2013, 1834, 2712-2721.	2.3	14
9	Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4138.	4.1	14
10	Replacement of the Human Topoisomerase Linker Domain with the Plasmodial Counterpart Renders the Enzyme Camptothecin Resistant. <i>PLoS ONE</i> , 2013, 8, e68404.	2.5	13
11	Role of Flexibility in Protein-DNA-Drug Recognition: The Case of Asp677Gly-Val703Ile Topoisomerase Mutant Hypersensitive to Camptothecin. <i>Journal of Amino Acids</i> , 2012, 2012, 1-8.	5.8	12
12	Mutation of Gly717Phe in human topoisomerase 1B has an effect on enzymatic function, reactivity to the camptothecin anticancer drug and on the linker domain orientation. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 860-868.	2.3	11
13	Topoisomerase IB: a relaxing enzyme for stressed DNA. , 2020, 3, 18-25.		7
14	In Vitro and In Silico Characterization of an Antimalarial Compound with Antitumor Activity Targeting Human DNA Topoisomerase IB. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7455.	4.1	5
15	From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge <i>Dendrilla antarctica</i> . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2022, 37, 1404-1410.	5.2	5
16	Real-time analysis of cleavage and religation activity of human topoisomerase 1 based on ternary fluorescence resonance energy transfer DNA substrate. <i>Archives of Biochemistry and Biophysics</i> , 2018, 643, 1-6.	3.0	3
17	The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance. <i>Archives of Biochemistry and Biophysics</i> , 2019, 663, 165-172.	3.0	1
18	Swapping of The N-Terminal Domain of Human Topoisomerase 1B with the Corresponding Counterpart Strongly Impairs Enzyme Activity. <i>Reports of Biochemistry and Molecular Biology</i> , 2020, 8, 366-375.	1.4	0